Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

246
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
246
Obedience01:08

Obedience

35.2K
According to obedience research, we may harm others under the forceful pressures of an authority figure (Milgram, 1974). How about if the inappropriate orders were delivered with less force? The increasing interdependence between nurses and physicians compelled Hofling and his colleagues to explore nurses’ reactions to a potentially harmful medical request made by the perceived authority figure, the doctor (Hofling, Brotzman, Dalrymple, Graves, & Pierce, 1966). In this situation,...
35.2K
Ethics in Research01:56

Ethics in Research

25.4K
Today, scientists agree that good research is ethical in nature and is guided by a basic respect for human dignity and safety. However, this has not always been the case. Modern researchers must demonstrate that the research they perform is ethically sound.
25.4K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Deuruxolitinib: New Approval.

Clinical drug investigation·2026
Same author

Bevifibatide: First Approval.

Drugs·2026
Same author

Correction: Ifupinostat: First Approval.

Drugs·2026
Same author

Ifupinostat: First Approval.

Drugs·2025
Same author

Fosrolapitant/Palonosetron: First Approval.

Drugs·2025
Same author

Nipocalimab: First Approval.

Drugs·2025
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
查看所有相关文章

相关实验视频

Updated: Jan 22, 2026

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.5K

雷米布鲁丁尼布:首次获得批准

Simon Fung1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|January 20, 2026
PubMed
概括
此摘要是机器生成的。

雷米布鲁丁尼布是一种新的口服布鲁顿氨酸激酶 (BTK) 抑制剂,已被批准用于成人慢性自发性疹 (CSU). 这标志着症状性CSU不对抗胰岛素药物反应的患者的显著进展.

更多相关视频

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

40.5K
Isolation and Derivation of Mouse Embryonic Germinal Cells
14:01

Isolation and Derivation of Mouse Embryonic Germinal Cells

Published on: October 22, 2009

16.6K

相关实验视频

Last Updated: Jan 22, 2026

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.5K
The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

40.5K
Isolation and Derivation of Mouse Embryonic Germinal Cells
14:01

Isolation and Derivation of Mouse Embryonic Germinal Cells

Published on: October 22, 2009

16.6K

科学领域:

  • 药理学 药理学是指药理学的学科.
  • 免疫学 免疫学 免疫学
  • 皮肤病学 皮肤病学

背景情况:

  • 慢性自发性疹 (CSU) 是一种使人虚弱的疾病,通常不耐标准治疗.
  • 布鲁顿的氨酸激酶 (BTK) 在免疫细胞激活中起着关键作用,与CSU的发病有关.

研究的目的:

  • 总结雷米布鲁丁尼布在CSU的发展里程碑.
  • 为了突出雷米布鲁丁尼布在症状性CSU的首次监管批准.

主要方法:

  • 对雷米布鲁丁尼布的临床前和临床开发数据的审查.
  • 对监管提交和批准时间表的分析.

主要成果:

  • 雷米布鲁丁尼布是一种选择性BTK抑制剂,已经经历了广泛的开发.
  • 首次批准于2025年9月30日在美国授予,用于症状性CSU的成年患者,尽管接受了H1-抗组胺药物治疗.
  • 随后在中国获得批准,在欧盟和日本正在进行审查.

结论:

  • 雷米布鲁丁尼布代表了CSU的新疗法选择.
  • 批准意味着在管理CSU方面迈出了一大步,为未满足需求的患者提供了希望.